SciELO - Scientific Electronic Library Online

 
vol.35 número2Incapacidad permanente y mortalidad prematura en una cohorte de afiliados a la Seguridad Social en España, 2004-2015Acceso a los servicios de salud en población inmigrante china residente en Sevilla, España índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Gaceta Sanitaria

versão impressa ISSN 0213-9111

Resumo

RODRIGUEZ-FEIJOO, Santiago  e  RODRIGUEZ-CARO, Alejandro. Pharmaceutical copayment in Spain after the 2012 reform from the user's perspective. Evidence of inequity?. Gac Sanit [online]. 2021, vol.35, n.2, pp.138-144.  Epub 29-Nov-2021. ISSN 0213-9111.  https://dx.doi.org/10.1016/j.gaceta.2019.09.009.

Objective

Identify what are the characteristics of the part of the population that says they cannot buy all the medicines prescribed by a public health doctor, relating them to the criteria that define the pharmaceutical co-payment system established by Royal Decree 16/2012, with the purpose of guiding changes that eliminate possible inequities.

Method

Association study and causal relationship between the difficulty to buy prescription drugs that users expressed through the survey called Health Barometer and a set of variables that reflect the degree of need for health services and the economic capacity, that is also part of the co-payment criteria, using multiple correspondence and regression analysis techniques.

Results

After the analysis of the data corresponding to the years 2013-2017, evidence has been found in favour of the hypothesis that the poorest users, as well as the working ones and those with worst health show greater difficulties in accessing the medicines which have been prescribed by a public health doctor and, consequently, changes are proposed in the copayment system aimed at eliminating or, at least, reducing such differences.

Conclusions

The results obtained are compatible with the hypothesis that the current copayment is perceived as a barrier to access necessary medicines by some sectors of the population. Although certain actions aimed at reducing this barrier can be derived from the work, more research that considers the opinion of the users is needed.

Palavras-chave : Health equity; Health expenditures; Economics; Pharmaceutical; Salaries and fringe benefits.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )